News Medical on MSN3d
Researchers find that blocking specific proteins in immune cells can reduce or reverse lung scarringA discovery at Duke-NUS Medical School offers new hope in the battle against pulmonary fibrosis, a debilitating lung ...
Researchers have identified YAP and TAZ as crucial regulators of macrophage-mediated pulmonary inflammation and fibrosis, ...
On Friday, during after-hours trading, Pliant Therapeutics announced it has voluntarily paused enrollment and dosing in the ...
The two positive studies mean that Boehringer can now seek approval for nerandomilast with a broad label claim in pulmonary ...
Pliant Therapeutics has pumped the breaks on a mid-stage trial of its lead liver disease drug on the advice of its safety ...
A discovery at Duke-NUS Medical School offers new hope in the battle against pulmonary fibrosis, a debilitating lung condition that progressively makes it harder for patients to breathe. Scientists ...
Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
In what one analyst called a “unique situation,” the company stopped dosing patients on the recommendation of trial monitors, ...
News Medical on MSN1d
AI-driven discovery unveils TNIK inhibition as anti-aging strategyA groundbreaking study led by researchers at Insilico Medicine has revealed the potential of TNIK inhibition as an innovative anti-aging strategy.
It is unclear why an independent data safety monitoring board recommended the suspension of Pliant’s Phase IIb/III BEACON-IPF ...
Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback